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Abstract
Background/Aims. Recently, peripheral blood mononu-
clear cell transcriptome analysis has identified genes that
are upregulated in relapsingminimal-change nephrotic syn-
drome (MCNS). In order to investigate protein expression
in peripheral bloodmononuclear cells (PBMC) from relaps-
ing MCNS patients, we performed proteomic comparisons
of PBMC from patients withMCNS in relapse and controls.
Methods. PBMC from a total of 20 patients were analysed.
PBMCwere taken from five patients with relapsingMCNS,
four in remission, five patients with other glomerular dis-
eases and six controls. Two dimensional electrophoresis
was performed and proteome patterns were compared.
Results.Automatic heuristic clustering analysis allowed us
to pool correctly the gels from the MCNS patients in the
relapse and in the control groups. Using hierarchical pop-
ulation matching, nine spots were found to be increased in
PBMC from MCNS patients in relapse. Four spots were
identified by mass spectrometry. Three of the four proteins
identified (L-plastin, α-tropomyosin and annexin III) were
cytoskeletal-associated proteins. Using western blot and
immunochemistry, L-plastin and α-tropomyosin 3 concen-
trations were found to be enhanced in PBMC from MCNS
patients in relapse.
Conclusions. These data indicate that a specific proteomic
profile characterizes PBMC from MCNS patients in re-
lapse. Proteins involved in PBMC cytoskeletal rearrange-
ment are increased in relapsing MCNS. We hypothesize
that T-cell cytoskeletal rearrangement may play a role in
the pathogenesis of MCNS by altering the expression of
cell surface receptors and by modifying the interaction of
these cells with glomerular cells.
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Introduction
Idiopathic nephrotic syndrome is the most frequent
glomerular disease in childhood. It is characterized by
massive proteinuria, and histopathological changes are re-
stricted to effacement of podocyte foot processes without
significant glomerular immune deposits [minimal-change
nephrotic syndrome (MCNS)]. Several clinical and experi-
mental studies underscore the implication of T-cells in the
pathogenesis ofMCNS. For example, immunogenic stimuli
such as viral infections, immunizations and allergens have
been shown to trigger nephrotic relapse. In addition, remis-
sions can be induced by steroids and calcineurin inhibitors
(ciclosporin and tacrolimus). The efficacy of thymodepen-
dent cell cytotoxic agents such as cyclophosphamide and
chlorambucil observed during MCNS relapses represents
further evidence implicating an immune pathogenesis [1].
Thus, MCNS is considered to be associated with T-cell dys-
function; however, the molecular link between the immune
system and the kidney is still unknown.
Recently, several groups attempted to identify the T-cell
genes that were involved in MCNS using a substractive
cDNA library [2] and serial analysis of gene expression
(SAGE) [3,4]. These studies revealed several differences
in the transcriptome of peripheral blood mononuclear cells
(PBMC) in relapsing MCNS.
In order to investigate the differences in protein expres-
sion in PBMC from relapsing MCNS patients, we per-
formed proteomic comparisons of PBMC from patients
with MCNS in relapse and remission, patients with other
glomerulopathies and non-proteinuric patients. Spots selec-
tively upregulated in MCNS in relapse were further identi-
fied by mass spectrometry.
Materials and methods
Patients
Samples were drawn from four groups of patients: five pa-
tients withMCNS in relapse, four in remission, five patients
with other glomerular diseases and six non-proteinuric con-
trols. For each patient, the clinical history and laboratory
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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data were obtained (Table 1). The criteria of the Interna-
tional Study of Kidney Disease in Children were used for
the diagnosis and management of MCNS [5].
PBMC collection
Blood samples were obtained from patients cared for at
the Children’s Hospital of Geneva and the Kinderspital of
Zurich. The study was approved by the local ethical com-
mittees. For each patient, 10 ml of blood was collected
in an Acid-Citric-Dextrose tube (BD Vacutainer, Becton
Dickinson, Franklin Lakes, NJ, USA) and PBMCwere sep-
arated by gradient centrifugation (Ficoll-Paque, Amersham
Biosciences, Freiburg, Germany) and frozen in autologous
plasma with DMSO in nitrogen. In order to compare our
results with those obtained from non-specific stimulation
of PBMC, a group of stimulated PBMC from controls was
included, and stimulation was achieved using phytohemag-
glutinin (PHA-P) (Sigma, St Louis, MO, USA) as follows:
cells were resuspended in RPMI (Invitrogen System, CA,
USA) and 20% autologous plasma with PHA 10 µg/ml at a
density of 2× 106 cells/ml. Cells were incubated overnight
at 37◦C/5% CO2. After gentle centrifugation, supernatant
was discarded and cell pellet frozen at −80◦C.
T-cell enrichment of PBMC
T-cells were isolated from PBMC using immunomagnetic
negative cell selection (StemSep, StemCell Technologies
Inc., British Columbia, Canada). PBMC were suspended in
a mixture of antibodies that included anti-CD14, CD16,
CD19, CD56 and anti-glycophorin A (StemSep ANTI-
BODY COCKTAIL, StemCell Technologies Inc.) and in-
cubated with a magnetic colloid (StemSep MAGNETIC
COLLOID, StemCell Technologies Inc.). The resulting cell
suspension was loaded on a column and an enriched sus-
pension of unlabelled cells was collected. Cell purity of
T-cell enriched PBMC and T-cell and B-cell repartition of
PBMC obtained from controls, MCNS patients in relapse
and remission were tested by FACS using CD3, CD14 and
CD19 antibodies (DAKO, Denmark).
2D PAGE
Urea was from Merck (Darmstadt, Germany), Thiourea
was from Fluka (Buchs, Switzerland) and Zwittergen from
Calbiochem (CA, USA). CHAPS and Iodoacetamide were
from Sigma and DTT from Amersham Biosciences.
PBMC isolated from each patient’s sample were resolved
in a single 2D gel. Gels were performed according to Go¨rg
with some modifications [6]: cellular proteins (125 µg of
proteins from 1 × 106 cells) were solubilized using a ly-
sis buffer containing 7 M urea, 2 M thiourea, 2% CHAPS,
2% Zwittergen and 65 mM dithiothreitol [7]. In-gel re-
hydration was performed overnight at room temperature.
Isoelectrofocusing was performed on the Multiphor II sys-
tem (Amersham Biosciences) under paraffin oil using a
nonlinear IPGs pH range 3–10, 18 cm (Immobiline DryS-
trips 3–10 NL, Amersham Biosciences). The voltage was
progressively increased to a maximum of 3500 V and for a
total of 80 kVh.
Before the second dimension, strips were equilibrated
in a solution containing 6 M urea, 50 mM Tris–HCl, 30%
glycerol, 2% SDS, 1% DTT for 20 min, and a second time
in the same solution containing traces of bromophenol blue
and 4.8% iodoacetamide. The second dimension was per-
formed using precast polyacrylamide gels 12–14%gradient
(5–120 kDa) (ExcelGel XL SDS 12–14, Amersham Bio-
sciences). Migration was started at 150 V, 20 mA for 1 h,
and 800 V, 35 mA for 3 h, at 18◦C. Analytic gels were
silver stained (Silver staining kit, Amersham Biosciences)
and dried overnight. For pattern evaluation, gel images were
captured using CCD Fujilas 1000 Plus (Fujifilm Medical
Systems, USA).
To demonstrate differences in protein expression in
the PBMC from relapsing MCNS patients, we used two
methods, heuristic clustering and hierarchical population
matching.
Heuristic clustering. Heuristic clustering was performed
for the automatic classification of a first set of gels using a
previously described algorithm [8]. 2D gels were obtained
from four different samples of PBMC of MCNS patients in
relapse and from three samples of control PBMC. The algo-
rithm provides the possibility of blindly classifying similar
gels into a determined number of classes (in this case, re-
lapse and controls).
Hierarchical population matching. For each gel, spot de-
tection, landmark editing and pattern matching were per-
formed using the Melanie software version 3.0 (Genebio,
Geneva, Switzerland). Gels were compared using a hier-
archical population matching. For each condition studied,
gels were matched and the group of spots merged into an
average gel. All average gels were added to a mastergel that
served as a reference gel. All gels, independently of their
clinical classification, were then matched with the refer-
ence gel. For spot quantification, a relative spot volume
determination (volume of a spot/volume of all spots in the
gel) was used as it is a normalized value that is relatively
independent of variations between gels due to experimental
design. Gels were then matched and histograms for groups
based on normalized % volume of the spots were recorded,
using the central tendency as the mean value and the mean
square deviation as the dispersion value. The spots display-
ing a change in their expression between classes greater
than the twofold factor (determined from the mean) were
considered for protein identification.
In order to proceed to the identification of the selected
spots, preparative gels were performed with a higher pro-
tein load (0.6–1 mg of proteins from 5–8 × 106 cells).
For protein detection, gels were fixed for 30 min in 10%
methanol and 7% acetic acid and stained overnight us-
ing SYPRO Ruby (Molecular Probes, USA) [9]. Gels
were digitalized at 470 nm and spots of 1.4 mm diam-
eter picked using a 300 nm light. Gel plugs were then
destained and incubated in 75% acetonitrile for 20 min.
For trypsinisation, gel plugs were incubated with trypsin
for 1 h at 37◦C and peptides extracted with an acetonitrile-
TFA solution. Identification was performed using a 4700
Proteomics Analyzer mass spectrometer (Applied Biosys-
tems, Foster City, CA, USA) mass spectrometer and an
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Table 1. Characteristics of patients used for 2D gels comparison. PBMC from two patients (3 and 4) were analysed both in remission and in relapse
Patients Sex Age
(years)
Clinical diagnosis Years
since
diagnosis
Renal
biopsy
Steroid therapy Other treatment PU (g/l) Urinary
protein/creatinine
ratio (g/mol)
Plasma
protein
(g/l)
Plasma
albumin
(g/l)
Creatinine
clearance
(ml/min)
1 F 11 MCD remission 3 – N N 0.28 43.8 69 44 102
2 F 9 MCD remission 1.5 – N N 0.08 13.7 72 45 90
3 F 10.5 MCD remission 9 MCD Prednisone 40 mg Ciclosporine 200 mg 0.11 12.2 67 37 90
EOD Qday
4 M 4 MCD remission 1 MCD Prednisone 10 mg Ciclosporine 140 mg 0.03 6.0 61 31 113
EOD Qday
5 M 7 MCD relapse 1 – N N 10 2400.0 51 30 108
6 M 9 MCD relapse 5.5 – Prednisone 30 mg Levamisole 50 mg 5.12 1163.6 44 17 178
EOD EOD
3 F 14 MCD relapse 7 – Prednisone 5 mg N 4.16 343.8 46 18 142
EOD
4 F 10 MCD relapse 8 – Prednisone 60 mg Ciclosporine 200 mg 30 1435.4 48 11 121
EOD Qday
7 M 3 MCD relapse 0.5 – Prednisone 30 mg N 2.76 563.3 54 30 189
EOD
8 F 12.5 MPGN type 1 0.2 MPGN
type 1
N N 3.98 995.0 37 14 67
9 M 6.5 IgA 5 IgA N Enalapril 10 mg 2.25 239.0 63 NA 70
Qday
10 F 10.5 IgA 0.1 IgA N N 1.06 342.0 62 33 133
11 F 15 IgA 1.5 IgA N Enalapril 10 mg 1.09 129.8 68 40 87
Qday
12 M 17 IgA 3 IgA N Enalapril 15 mg NA 33.0 68 40 79
Qday
MCD: minimal-change disease; IgA: IgA nephropathy; MPGN: membranoproliferative glomerulonephritis; N: no treatment; EOD: every other day; Qday: once a day; PU: proteinuria;
NA: non-available.
Creatinine clearances were calculated using the Schwartz formula.
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α-cyano-4-hydroxy-cinnamic acid matrix (Sigma). The
identified peptides were matched against the Mascot
database for protein identification.
Western blots
Themouse anti-human L-plastin antibody (clone LPL4A.1)
(NeoMarkers, CA, USA) was used at 1/2500 in a blocking
buffer (5% Nonfat Milk in Tween 20 Tris buffered saline).
Total PBMC extracts (2 × 106 cells) were solubilized in
a lysis buffer with 0.1% sodium dodecyl sulfate (SDS),
1% NP40, 1% Na-deoxycholate and protease inhibitor
Complete (Roche Applied Science, IN, USA). Cell lysates
were resolved by 10% SDS gel electrophoresis [10] and
transferred to the polyvinyl difluoride (PVDF) membrane
(Hybond-P, Amersham Biosciences) by electroblotting
using semi-dry blotting and a discontinuous buffer system.
Immunoblotting was performed as described [11] and
detection was performed using enhanced chemolumines-
cence (ECL + kit, Amersham Biosciences). Membranes
were exposed for 5–20 s to Hyperfilm ECL (Amersham
Biosciences) in an X-ray film cassette. Variations among
samples were assessed by incubation with the anti-GAPDH
antibody (1/2500). After revelation, films were scanned
with an image scanner (Amersham Biosciences) and
quantified with the Image Quant TL software (Amersham
Biosciences).
Immunohistochemistry
The mouse anti-human L-plastin antibody was purchased
from Abcam (Cambridge, UK), mouse anti-human α-
tropomyosin 3 antibody (clone CG1) fromNeoMarkers and
rabbit anti-human annexin III from Genex Bioscience Inc.
(CA, USA).
PBMC were cytospun at 105 cells/slide, fixed with
paraformaldehyde 4% and permeabilized with 0.3% Triton
X-100 for 5 min at room temperature. Cells were incubated
in the blocking solution (2% BSA in PBS) for 30 min at
room temperature, and incubated overnight at 4◦C with the
antibody (1/100 for L-plastin, 1/1000 for α-tropomyosin 3).
Slides were washed three times with PBS, and then in-
cubated with the goat anti-mouse FITC labelled antibody
(1/200 in the blocking solution).
Images were obtained using an Axiovert 200 M micro-
scope (Zeiss, Germany) and processed with the Adobe Pho-
toshop 5.5 software. All images were analysed according to
a modification of the method of Chen et al. [12]. For each
protein, a total of 70 cells were individually photographed
at 100×magnification and scored by two investigators who
were blinded to the identity of the samples. The samples
were then scored from 0 (no signal) to 3 (highest expres-
sion) for L-plastin, α-tropomyosin 3 and annexin III. Each
blinded experiment was carried out on three independent
occasions.
Statistics
Results are given in terms of mean ± standard devia-
tion. The differences in expression levels between relaps-
ing MCNS and control conditions and patients with other
glomerular diseases and control conditions for a given pro-
tein were assessed using the two-sample Mann–Whitney
test. The relationship between spot relative volume and
the patient’s steroid dosage was examined using linear re-
gression analysis. Differences were considered statistically
significant for P < 0.05.
Results
Comparison of T-cell enriched PBMC and PBMC
The 2D gel proteomes of T-cell enriched PBMC and un-
fractionated PBMCwere compared using theMelanie Soft-
ware. For T-cells, an average of 1248 ± 166 spots (mean ±
SD) and for PBMC, an average of 1254 ± 29 spots (mean
± SD) were detected per gel. The matching between T-cell
gels and PBMC did not reveal anymajor pattern differences
as spots present in T-cell gels were accurately represented in
PBMC gels. Due to limited amount of samples, all further
comparisons were carried out on PBMC. The percentage of
T-cells in PBMC obtained from controls was 70.0 ± 6.5%,
72.1 ± 9.1% in MCNS patients in relapse and 77.7 ± 3.0%
in MCNS in remission (n = 5; P = 0.437). The percentage
of B-cells was 16.0± 1.9%, 14.9± 2.5% and 10.4± 1.0%,
respectively (n = 5, P = 0.126).
Protein alterations in PBMC from MCNS patients
Heuristic clustering analysis. The heuristic clustering
analysis after the image processing of seven 2D gels (three
gels of PBMC from control patients and four gels of PBMC
from patients with MCNS in relapse) correctly classified
the gels into the two groups.
2D gel comparison. In order to determine which proteins
were upregulated in PBMC of patients with MCNS in re-
lapse, five groups of samples were processed: a group of
five samples of PBMC from patients with MCNS in re-
lapse, a group of four samples from patients with MCNS
in remission, a group of five samples of PBMC from pa-
tients with other glomerular diseases, a control group of six
samples from non-proteinuric patients and a group of five
samples of PHA-stimulated PBMC from control patients.
A gel with a pH range 3–10 was performed for each
sample (total of 25 gels). A reproducible protein pattern
was achieved and an average of 1180 ± 301 spots per gel
was detected. After image acquisition, gels were analysed
using the Melanie software. Prior to matching, landmark
editing was performed and a synthetic gel was created for
each group of samples. Each gel wasmatched to amastergel
in order to compare proteome patterns.
After gel analysis, nine spots with an increased expres-
sion in gels from patients with MCNS in relapse were
selected for identification from which two could not be
picked on the preparative gel and therefore could not
be further analysed. Of the remaining seven spots anal-
ysed with the mass spectrometer, three had a very weak
mass spectrometry signal and could not be further anal-
ysed and four spots were identified with a good database
matching. The four proteins identified were L-plastin,
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Fig. 1. Histogram showing the relative volume of the spots analysed by
mass spectrometry: for spot quantification, a relative spot volume deter-
mination (volume of a spot/volume of all spots in the gel) was used as it
is a normalized value that is relatively independent of variations between
gels due to experimental design. On the x-axis, each letter represents a
single gel and each number represents a group (1: relapse, 2: remission,
3: control, 4: other glomerular diseases, 5: PHA stimulation). The y-axis
represents the relative volume of the spot.
Table 2. Spots with an upregulated expression in PBMC from patients
with relapsing MCNS
Spot no. Protein name Relapse versus
control and
remission
Other glomerular
diseases versus
control and
remission
2 Annexin III 0.04 0.631
13 Glutathione peroxidase 0.009 1.000
15 α-Tropomyosin 0.01 0.254
6 L-plastin 0.05 (0.010a) 0.699
aCompared to control patients only.
The differences in expression levels between MCNS patients in relapse
and controls and in patients with other glomerular diseases and controls
for a given protein were assessed by using the two-sample Mann–Whitney
tests.
annexin III, α-tropomyosin 3 and glutathione peroxidase
(Figure 1 and Table 2). The proteins characteristics are de-
scribed in Table 3.
The relationship between spots’ relative volume in the
patient’s gel and the patient’s daily steroid exposure showed
an r2 at 0.17 (P = 0.15) for L-plastin, 0.13 (P = 0.20) for
annexin III, 0.07 (P = 0.36) for α-tropomyosin 3 and 0.18
(P = 0.13) for glutathione peroxidase.
Western blots and immunocytochemistry of L-plastin,
α-tropomyosin 3 and annexin III. Densitometric analysis
of L-plastin western blots was performed in PBMC protein
extracts from seven MCNS patients in relapse and eight
controls. L-plastin concentration was 2010 ± 168 DU in
controls and 2588 ± 193 DU in MCNS patients in relapse
(P < 0.05). The L-plastin–GAPDH ratio increased from
0.9 ± 0.08 to 1.2 ± 0.09 (P < 0.05).
The expressions of L-plastin, α-tropomyosin 3 and an-
nexin III were also examined immunocytochemically in
PBMC from MCNS patients in relapse (n = 3) and from
controls (n = 3). The expression of L-plastin and α-
tropomyosin 3 was enhanced in PBMC from MCNS pa-
tients in relapse (Figure 2). Scores were 1.33 and 1.55 in
controls and 2.19 and 2.56 in relapse (P < 0.0001). No
changes were observed for annexin III.
Discussion
This studywas designed to identify proteins specifically up-
regulated in mononuclear cells ofMCNS patients in relapse
using a proteomic approach. Comparisons of mononuclear
cell proteomic maps from patients with MCNS in relapse,
remission, other proteinuric conditions and controls were
performed using heuristic clustering and hierarchical pop-
ulation matching. Heuristic clustering takes into account
several small differences in spot patterns that may not be
individually recognized by the hierarchical population. The
ability of heuristic clustering to correctly classify the gels
into two groups (MCNS patients in relapse and controls)
demonstrates the existence of a specific pattern of spots in
gels of PBMC from patients with MCNS in relapse.
Among the four upregulated spots in MCNS in relapse
identified by hierarchical population matching and mass
spectrometry, three were cytoskeletal-associated proteins:
L-plastin, annexin III and α-tropomyosin.
The first protein, L-plastin, is a leukocyte-actin-binding
protein and recent studies have implicated L-plastin phos-
phorylation in the regulation of β2 integrin function [13]
whose activation and binding to ICAM-1 on the endothelial
surface are part of the process of homing in leukocytes. Fur-
thermore, phosphorylation of L-plastin was found to play
a crucial role for the transport of activation-induced recep-
tors to the surface of T-cells [14]. L-plastin’s transcript was
found to be upregulated using a cDNA library in PBMC
from MCNS patients in relapse [2], and in our study, the
upregulation of L-plastin was confirmed by western blot
and immunochemistry. Therefore, the upregulation of L-
plastin could be implicated in T-cell activation in MCNS in
relapse.
The second protein, annexin III, is an abundant neu-
trophil cytosolic protein that was found to influence the
function of membrane constituents by association and dis-
sociation with the inner membrane in concert with calcium
oscillations [15]. Furthermore, a 36 kDa annexin III variant
has been identified in human monocytes and could play a
specific role in these cells [16].
The third protein, α-tropomyosin, binds to actin fila-
ments in muscle and non-muscle cells and is implicated in
stabilizing cytoskeleton actin filaments.
The upregulation of these three cytoskeletal-associated
proteins in MCNS in relapse might therefore emphasize
a potential role of T-cell activation in the pathogenesis of
MCNS.
Several authors had analysed mononuclear cells of
MCNS patients using genomics: Sahali isolated 84 tran-
scripts using a subtracted cDNA library screening. Among
the 42 known transcripts, 18 were involved in the T-cell
signalling cascade, including genes encoding cytoskeleton-
associated proteins such as L-plastin, grancalcin and
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Table 3. Spots with an upregulated expression in relapsing MCNS: mass spectrometry and Swiss-Prot database results with entry name, accession
number, theoretical isoelectric point, molecular weight and major functions
Spot no. Protein name No. of peptide
observed by PMF
MASCOT
score
Sequence
coverage (%)
Swiss-Prot
accession no.
MW (kDa) pI Major functions
2 Annexin 3 4 69 13 P12429 36.4 5.6 Family of calcium binding
proteins. Implicated in
exocytose,
formation/modulation of ion
channels and membrane
attachment of cytoskeletal
elements
6 L-plastin 10 87 21 P13796 70.3 5.2 Leukocyte-actin-binding protein.
Might be implicated in integrin
activation and adhesion via its
phosphorylation
13 Glutathione
peroxidase
na 41 na P07203 21.9 6.1 Regulation of phospholipid
turnover and protection against
oxydative stress injury
15 α-Tropomyosin
isoform TM3
na 23 na P06753 32.8 4.7 Binds to actin filaments in
muscle and nonmuscle cells.
Implicated in stabilizing
cytoskeleton actin filaments
na: not available.
Fig. 2. The expression of L-plastin and α-tropomyosin observed by im-
munohistochemistry. The expression of L-plastin in PBMC from controls
(a) and MCNS patients in relapse (b). The expression of α-tropomyosin
in PBMC from controls (c) and MCNS patients in relapse (d).
Fyb/Slap [2]. Using SAGE methodology, Mansour found
179 tags over-represented in the relapse library includ-
ing 21 transcripts coding for T-cell surface markers, nu-
merous transcripts encoding proteins involved in protein
metabolism, energy supply and signal transduction [3]. Us-
ing the same SAGE technology, Okuyama found 15 genes
upregulated in relapsing MCNS [4]. These studies were
conducted in only isolated individuals and in our exper-
iments we used a hierarchical population matching com-
paring several individuals in each group to minimize the
individual differences not related to the disease itself. Stud-
ies have been published recently that compare both genes
and proteins that are differentially expressed in two biolog-
ical conditions [17]. The conclusion drawn by the authors
is that there is no or only a moderate correlation between
differential RNA and protein expression.
In our study, only a few spots could be identified as
upregulated in MCNS in relapse and this might be due to
methodological constraints: only spots with a mean twofold
increase in relative volume were selected for identification
and the proteomic technique itself is poorly efficient in sep-
arating basic proteins, proteins with low molecular weight
and membrane proteins. Further, proteomic analysis using
the DIGE technology or isolation of membrane proteins
could help us identify more proteins even though a higher
amount of material would be needed in order to proceed
with these experiments.
We were also able to address the question of the speci-
ficity of the changes in protein expression. The analysis
of multiple control conditions (remission, other glomerular
diseases and nonproteinuric patients) was conducted in or-
der tominimize differences in protein expression secondary
to treatment or other factors not related to the MCNS dis-
ease itself. As proteins identified in MCNS patients in re-
lapse were implicated in cell activation, we obtained a non-
specific stimulation of PBMC from control patients using
a mitogen agent, PHA. None of the identified spots were
upregulated in the PHA-stimulated PBMC thus indicating
that the observed modifications were unlikely secondary to
non-specific stimulation of PBMC.
In our study population, four of the five patients with
MCNS in relapse and two of the four patients with
MCNS in remission were treated with prednisone every
other day, and we can address the question of the influ-
ence of the steroid therapy on protein expression. The
Proteomic analysis of mononuclear cells in MCNS 155
immunosuppressive effect of glucocorticoids on peripheral
T-cells has beenwidely described in the literature [18] and in
proteomic studies, a recent paper fromBilling [19] analysed
the cortisol-mediated stress response in a humanmonocytic
cell line THP-1 by incubating them with cortisol for 48 h.
Proteomic maps were then compared using the DIGE tech-
nology. Differentially expressed proteins (>1.5-fold) were
selected for identification. Upregulation of 28 proteins was
found with the highest upregulation for FKBP51. Other
identified proteins were involved in cytoskeleton, chap-
eroning, metabolism, transcription and immune response.
L-plastin and isoforms were found to be upregulated 1.5- to
2.2-fold. In our study, patients in both groups (relapse and
remission) were treated with steroids and amongst the four
patients on steroid with MCNS in relapse, only one was on
a high dose (60 mg) and one was on a very low mainte-
nance dose (5 mg). No correlation was found between daily
steroid exposure and expression of L-plastin, annexin III,
α-tropomyosin and glutathione peroxidase, and therefore,
steroid treatment did not seem to have affected our results
significantly.
In PBMC from relapsing MCNS patients, genomic stud-
ies have shown an upregulation of genes implicated in T-
lymphocyte cytoskeletal modifications leading to cell sig-
nalling [2]. By using proteomics, our study showed upregu-
lation of cytoskeletal-associated proteins involved in T-cell
activation in MCNS in relapse thus providing further evi-
dence for the link between the immune system and the renal
cells in MCNS. We could therefore hypothesize that T-cell
cytoskeletal rearrangement plays a role in the pathogenesis
of MCNS by altering the expression of cell surface recep-
tors and by modifying the interaction of these cells with
glomerular cells.
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